By Adria Calatayud
Roche Holding said an experimental obesity drug it is jointly developing with Denmark's Zealand Pharma met its primary goal in a midstage trial by helping patients lose weight.
The drug candidate, petrelintide, led to meaningful weight loss in people who are overweight and living with obesity when administered in once-weekly injections after 28 weeks of treatment, meeting the main goal of the Phase 2 study, the Swiss pharmaceutical giant said Thursday. At week 42, petrelintide achieved a mean body-weight reduction of up to 10.7%, it added.
The company said the data support further development of the drug candidate in chronic weight management on its own or in combination with other drugs due to its tolerability.
The company said petrelintide showed a favorable tolerability profile, comparable to placebo.
Petrelintide is one of several obesity-drug candidates Roche has in its pipeline, as the drugmaker seeks to build a franchise to compete with Eli Lilly and Novo Nordisk. The company previously said it sees annual peak sales potential of more than $3 billion for the drug candidate.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
03-05-26 1446ET
